GlassScriptPhysician profile
Crystal Martin
NPI 1003577768
$3,316.58
in general payments reported to CMS, 2019-2025
21 companies · $1,702 in 2025
The $1,702 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $66.66 · 2024: $1,548 · 2025: $1,702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,316.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $681.25 | 2024-2025 | Descovy, Biktarvy, Epclusa |
| Novo Nordisk INC | $416.00 | 2024-2025 | Wegovy |
| Viiv Healthcare Company | $393.36 | 2024-2025 | Dovato, Cabenuva |
| Abbvie INC. | $309.46 | 2024-2025 | |
| Ucb, INC. | $248.52 | 2025 | Bimzelx |
| Emd Serono, INC. | $153.78 | 2025 | Serostim |
| Madrigal Pharmaceuticals | $144.13 | 2024 | Rezdiffra |
| Verrica Pharmaceuticals INC. | $124.99 | 2024 | Ycanth |
| Incyte Corporation | $124.98 | 2025 | Opzelura |
| Aimmune Therapeutics, INC. | $124.78 | 2024 | |
| Merck Sharp & Dohme LLC | $101.62 | 2024 | Delstrigo, Pifeltro |
| Exact Sciences Corporation | $75.48 | 2024-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $75.11 | 2024-2025 | Korlym |
| Theratechnologies INC. | $69.42 | 2025 | Trogarzo, Egrifta |
| Lilly USA, LLC | $67.38 | 2024-2025 | Mounjaro, Zepbound |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $66.66 | 2023 | Nexplanon |
| Glaxosmithkline, LLC. | $39.25 | 2025 | Arexvy, Shingrix |
| Dexcom, INC. | $36.06 | 2024 | Dexcom G6 Transmitter |
| Napo Pharmaceuticals INC | $26.34 | 2024 | Mytesi |
| Phadia US INC. | $19.07 | 2025 | Immunocap |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.94 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.